Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion.

The British journal of ophthalmology·2026
Same author

Vascular endothelial growth factor inhibitors outcomes in good vision eyes with neovascular age-related macular degeneration: Fight Retinal Blindness! SPAIN Report 4.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Faricimab for recalcitrant neovascular age-related macular degeneration: a real-life study following aflibercept nonresponse.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Genotype-Phenotype Correlations in ABCA4-Associated Retinopathy: Insights From a Spanish Cohort of 245 Patients.

Investigative ophthalmology & visual science·2026
Same author

Correction: Tomographic Differences in Thin Corneas Following DMEK in Fuchs Dystrophy: A Case-Control Study.

Ophthalmology and therapy·2025
Same author

Tomographic Differences in Thin Corneas Following DMEK in Fuchs Dystrophy: A Case-Control Study.

Ophthalmology and therapy·2025

Related Experiment Video

Updated: Apr 24, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

9.6K

Epimacular brachytherapy for wet AMD: current perspectives.

Ricardo P Casaroli-Marano1, Socorro Alforja2, Joan Giralt2

  • 1Instituto Clínic de Oftalmología (Hospital Clínic de Barcelona), University of Barcelona, Barcelona, Spain ; Department of Ophthalmology and Visual Sciences, Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Sao Paulo, Brazil.

Clinical Ophthalmology (Auckland, N.Z.)
|September 12, 2014
PubMed
Summary
This summary is machine-generated.

Epimacular brachytherapy (EMBT) shows promise as a combination therapy for wet age-related macular degeneration (AMD). However, current clinical trial data is insufficient to support its routine use in treating this common cause of blindness.

Keywords:
combined therapyintravitreal therapymacular degenerationradiationvascular endothelial growth factorvitrectomy

More Related Videos

Enrichment of Bruch's Membrane from Human Donor Eyes
10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

12.2K
Culturing of Retinal Pigment Epithelial Cells on an Ex Vivo Model of Aged Human Bruch's Membrane
08:32

Culturing of Retinal Pigment Epithelial Cells on an Ex Vivo Model of Aged Human Bruch's Membrane

Published on: April 12, 2018

13.4K

Related Experiment Videos

Last Updated: Apr 24, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

9.6K
Enrichment of Bruch's Membrane from Human Donor Eyes
10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

12.2K
Culturing of Retinal Pigment Epithelial Cells on an Ex Vivo Model of Aged Human Bruch's Membrane
08:32

Culturing of Retinal Pigment Epithelial Cells on an Ex Vivo Model of Aged Human Bruch's Membrane

Published on: April 12, 2018

13.4K

Area of Science:

  • Ophthalmology
  • Medical research

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 60.
  • AMD presents as geographic atrophy (dry AMD) or neovascular (wet AMD).
  • Wet AMD causes significant central vision loss due to choroidal neovascularization.

Purpose of the Study:

  • To evaluate the efficacy and safety of epimacular brachytherapy (EMBT) as a combination therapy for wet AMD.
  • To assess the potential of EMBT alongside anti-vascular endothelial growth factor (anti-VEGF) agents.

Main Methods:

  • Combination therapy involving EMBT and anti-VEGF agents.
  • Clinical trials were conducted to gather efficacy and safety data.

Main Results:

  • EMBT demonstrated an acceptable efficacy and safety profile when used in combination therapy.
  • Current clinical trial results are not yet sufficient to recommend routine EMBT use.

Conclusions:

  • EMBT is a potential adjunctive treatment for wet AMD.
  • Further research and clinical trials are needed to validate the routine use of EMBT for wet AMD.